Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB)

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 139-147

  Ernsberger, Paul ^a   Ishizuka, Tatsuya ^a   Liu, Sha ^a   Farrell, Craig J ^a   Bedol, David ^a   Koletsky, Richard J ^a   Friedman, Jacob E ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; ARTICLE; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; FEMALE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 4; HYPERTENSION; HYPOGLYCEMIC AGENTS; IMIDAZOLES; INSULIN; LIVER; MALE; MONOSACCHARIDE TRANSPORT PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; OBESITY; PHOSPHOPROTEINS; PHOSPHORYLATION; RATS; RATS, INBRED SHR; RATS, SPRAGUE-DAWLEY; RECEPTOR, INSULIN; TYROSINE;

EID: 0032912061     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Anderson EA, Hoffman RP, Balon TW, Sinkey CA and Mark AL (1991) Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87:2246-2252.
2. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10.
3. Borkman M, Storlein LH, Pan DA, Jenkins AB, Chisholm DJ and Campbell LV (1993) The relationship between insulin sensitivity and the fatty-acid composition of skeletal muscle phospholipids. N Engl J Med 328:238-244.
4. Belivacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA and Ferrannini E (1987) Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. Metab Clin Exp 36:323-329.
5. DiTullio NW, Cielinski L, Matthews WD and Storer B (1984) Mechanisms involved in the hyperglycemic response induced by clonidine and other alpha-2 adrenoceptor agonists. J Pharmacol Exp Ther 228:168-173.
6. Ernsberger PR, Estbrooks KL, Christen MO and Schafer SG (1992) A second generation of centrally acting hypertensive agents acts on putative I1-imidazoline receptors. J Cardiovasc Pharmacol 20 (Suppl 4):S1-S10.
7. 1-imadazoline receptors: definition, characterization, distribution and transmembrane signaling. Ann NY Acad Sci 763:22-42.
8. Ernsberger P, Koletsky RJ, Collins LA and Bedol D (1996) Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiouasc Drugs Ther 10:275-282.
9. Ernsberger P, Friedman JE and Koletsky RJ (1997) The I1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease. J Hypertension 15 (Suppl 1):S9-S23.
10. Felley CP, Felley EM, van Melle GD, Frascarolo P, Jequier E and Felber JP (1989) Impairment of glucose disposal by infusion of triglycerides in humans: Role of glycemia. Am J Physiol 256:E747-E752.
11. Friedman JE, Ishizuka T, Liu S, Farrell CJ, Bedol D, Kaung HL, Koletsky RJ and Ernsberger P (1997) Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273:E1014-E1023.
12. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ and Dohm GL (1995) Insulin receptor phosphorylation, IRS-1 phosphorylation, and phosphatidylinositol 3-kinase are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95:2195-2204.
13. Henriksen EJ, Jacob S, Fogt DL, Youngblood, EB and Godicke J (1997) Antihypertensive agent moxonidine enhances muscle glucose transport in insulin resistant rats. Hypertension 30:1560-1565.
14. Hiraoka J, Hosoda K, Ogawa Y, Ikeda K, Nara Y, Masuzaki H, Takaya K, Nakagawa K, Mashimo T, Sawamura M, Koletsky RJ, Yamori Y and Nakao K (1997) Augmentation of obese (ob) gene expression, and leptin secretion in obese spontaneously hypertensive rats (obese SHR or Koletsky rats). Biochem Biophys Res Commun 231:582-585.
15. Kaan EC, Bruckner R, Frohly P, Tulp M, Schafer SG and Ziegler D (1995) Effects of agmatine, and moxonidine on glucose metabolism: An integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 5 (Suppl 1):19-27.
16. Kahn CR (1994) Banting Lecture: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084.
17. Koletsky RJ and Ernsberger P (1992) Obese SHR (Koletsky rat): A model for the interactions between obesity and hypertension, in Genetic Hypertension (Sassard J ed) pp 373-375, John Libbey, London.
18. Krotkiewski M, Bjorntorp P, Sjostrom L and Smith U (1983) Impact of obesity on metabolism in men and women. J Clin Invest 72:1150-1162.
19. Knutson V (1991) Proteolytic processing of the insulin receptor β subunit is associated with insulin-induced receptor down-regulation. J Biol Chem 266:15656-15662.
20. Landsberg L (1993) Diabetes, obesity, and hypertension: Role of insulin and the sympathetic nervous system. Cardiovasc Risk Factors 3:153-158.
21. Lithell HOL (1991) Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14:203-209.
22. Maheux P, Jeppesen J, Sheu WHH, Hollenbeck CB, Clinkingbeard C, Greenfield MS, Chen Y-DI and Reaven GM (1994) Additive effects of obesity, hypertension, and type 2 diabetes on insulin resistance. Hypertension 24:695-698.
23. Periris AN, Mueller RA, Smith GA, Struve MF and Kissebah AH (1986) Splanchnic insulin metabolism in obesity. J Clin Invest 78:1648-1657.
24. Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346-356.
25. Pollare T, Lithell H and Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873.
26. Randle PJ, Garland PB, Hales CN and Newsholme EA (1963) The glucose-fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789.
27. Randle PJ, Kerbey AL and Espinal J (1988) Mechanisms decreasing glucose oxidation in diabetes and starvation: Role of lipid fuels and hormones. Diabetes Metab Rev 7:623-638.
28. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37:1595-1607.
29. Rice KM, Turnblow MA and Garner CW (1993) Insulin stimulates the degradation of IRS-1 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 190:961-967.
30. Robertson RP, Halter JB and Port D (1976) A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. J Clin Invest 57:791-795.
31. Rosen P, Ohly P and Gleichmann H (1997) Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertension 15:31-38.
32. Saad MJ, Araki E, Miralpeix M, Rothenberg PL, White MF and Kahn CR (1992) Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 90:1839-1849.
33. Sako Y and Grill VE (1990) A 48 hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and β-cell oxidation through a process likely coupled to fatty acid oxidation. Endocrinology 127:1580-1589.
34. Storlein LH, Jenkins AB, Chisholm DJ, Pascoe WS, Khouri S and Kraegen EW (1991) Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and w-3 fatty acids in muscle phospholipid. Diabetes 40:280-289.
35. Swislocki A and Tsuki A (1993) Insulin resistance and hypertension: glucose intolerance, hyperinsulinemia, and elevated free fatty acids in the lean spontaneously hypertensive rat. Am J Med Sci 306:282-286.
36. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, Nakao K and Koletsky RJ (1996) Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 14:203-205.
37. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T and Terauchi Y (1994) Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372:182-186.
38. Vaag A, Skott P, Damsbo P, Gall M-A, Richter EA and Beck-Nielson H (1991) Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with noninsulin dependent diabetes mellitus. J Clin Invest 88:1282-1290.
39. Wang X, Rondu F, lamouri A, Dokhan R, Marc S, Touboul I, Pfeiffer B, Manechez D, Renard P, Guardiola-Lemaitre B, Godfroid JJ, Ktorza A and Penicaud L (1995) Effect of S-21663 (PMS 812), an imidazoline derivative, on glucose tolerance and insulin secretion in a rat model of type II diabetes. J Pharmcol Exp Ther 278:82-89.
40. White MF and Kahn CR (1994) The insulin signaling system. J Biol Chem 269:1-4.
41. Worm D, Henriksen JE, Vaag A, Thye-Ronn P, Melander A, Beck-Nielsen H (1994) Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox on insulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocinol Metab 78:717-721.
42. Zavaroni I, Dall'Aglio E, Bonora E, Alpi O, Passen M and Reaven GM (1987) Evidence that multiple risk factors for coronary artery disease exist in persons with abnormal glucose tolerance. Am J Med 83:609-612.
43. Zou Y-P and Grill VE (1994) Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion, and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870-876.